Department of Internal Medicine, Hospital Universitario Araba, Calle Jose Atxotegi s/n, 01009, Vitoria, Spain.
Clinical Research Unit, BioAraba Health Research Institute, Hospital Universitario Araba, Calle Jose Atxotegi s/n, 01009, Vitoria, Spain.
Rheumatol Int. 2018 Feb;38(2):229-238. doi: 10.1007/s00296-017-3878-z. Epub 2017 Nov 10.
To investigate the association of age and other factors with thrombosis risk in antiphospholipid antibody (aPL) carriers, a retrospective observational study was conducted in a cohort of patients with medium-high aPL titres recruited in a tertiary care hospital. Assuming an age difference of 9.8 years between patients with and without thrombosis, we estimated that a sample size of 70 participants was required. Several variables besides age including gender, vascular risk factors, inherited thrombophilias, non-thrombotic clinical manifestations, laboratory parameters, aPL profile, length of aPL exposure, antithrombotic drugs and partial aPL score were assessed by univariate analysis followed by multivariate logistic regression. Outcomes were analysed by whether thromboses occurred before (model 1) or after (model 2) aPL detection. Seventy patients [50 females; median (interquartile range) baseline age: 46.99 (39.39-66.20) years] were followed for 2.59 (0.67-5.86) years. Overall, 18 and 5 thromboses were diagnosed applying models 1 and 2, respectively. Time to thrombosis after aPL detection was 2.10 (1.03-8.24) years. Age did not differ between patients with and without thrombosis using models 1 (p = 0.92) or 2 (p = 0.67). Instead, we identified other predictors of thrombosis, namely, lack of thromboprophylaxis [odds ratio (OR) 13.50, 95% confidence interval (95% CI) 1.02-178.05, p = 0.048] and length of aPL exposure (OR 1.41, 95% CI 1.04-1.92, p = 0.026) in model 2, while lupus anticoagulant showed a tendency to increase the risk (OR 7.10, 95% CI 0.86-58.78, p = 0.069) in model 1. Unlike age, lack of thromboprophylaxis, prolonged aPL exposure and lupus anticoagulant may increase the risk of thrombosis in aPL carriers.
为了研究年龄和其他因素与抗磷脂抗体(aPL)携带者血栓形成风险的关系,对一家三级医院中中高滴度 aPL 患者队列进行了回顾性观察研究。假设患有血栓形成和不患有血栓形成的患者之间的年龄差异为 9.8 岁,我们估计需要 70 名参与者的样本量。除年龄外,还评估了性别、血管危险因素、遗传性血栓形成倾向、非血栓形成临床表现、实验室参数、aPL 谱、aPL 暴露时间、抗血栓形成药物和部分 aPL 评分等多个变量。通过单变量分析评估这些变量,然后进行多变量逻辑回归。通过血栓形成是否发生在(模型 1)或发生在(模型 2)aPL 检测之前来分析结果。70 名患者[50 名女性;中位(四分位间距)基线年龄:46.99(39.39-66.20)岁]随访 2.59(0.67-5.86)年。总体而言,应用模型 1 和模型 2 分别诊断了 18 例和 5 例血栓形成。在 aPL 检测后发生血栓形成的时间为 2.10(1.03-8.24)年。应用模型 1(p=0.92)或模型 2(p=0.67),患者有或无血栓形成之间的年龄无差异。相反,我们确定了其他血栓形成的预测因素,即在模型 2 中,缺乏血栓预防(比值比[OR]13.50,95%置信区间[95%CI]1.02-178.05,p=0.048)和 aPL 暴露时间(OR 1.41,95%CI 1.04-1.92,p=0.026),而狼疮抗凝剂显示出增加风险的趋势(OR 7.10,95%CI 0.86-58.78,p=0.069)在模型 1 中。与年龄不同,缺乏血栓预防、aPL 暴露时间延长和狼疮抗凝剂可能会增加 aPL 携带者发生血栓形成的风险。